Reaction

Drug Specific Antibody reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,347 reports · 43 co-occurring drugs

As of the last recalculation, Drug Specific Antibody appears in 1,347 FAERS reports alongside 43 co-occurring drug terms. The strongest observed disproportionality signal is ANAKINRA (PRR 121.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Anakinra	119	121.5	122.4
Botulinum Toxin Type A	86	114.3	115.1
Infliximab	689	98.8	99.1
Telmisartan	82	75.5	75.9
Adalimumab-Fkjp	187	72.3	72.6
Adalimumab-Aaty	185	69.9	70.1
Adalimumab-Adaz	189	64.2	64.4
Naproxen Sodium Tablet, Coated	52	61.7	61.9
Naproxen Sodium, Coated Tablets	52	61.7	61.9
Naproxen Sodium 220Mg	52	61.6	61.8
Sumatriptan Succinate	85	55.4	55.6
Triamcinolone Acetonide Ointment Usp, 0.05%	63	43.6	43.7
Infliximab-Dyyb	65	36.1	36.1
Dexlansoprazole	89	35.2	35.3
Triamcinolone Acetonide	63	33.0	33.1
Bupropion	83	30.6	30.7
Mesalamine	103	30.6	30.7
Sulfasalazine	132	28.8	28.8
Human Immunoglobulin G	37	28.5	28.5
Rosuvastatin Calcium	48	27.3	27.3
Adalimumab	621	24.3	24.3
Naproxen	110	23.5	23.5
Budesonide	81	22.5	22.6
Venlafaxine	86	19.8	19.8
Tocilizumab	127	18.9	18.9
Hydroxychloroquine Sulfate	101	18.4	18.5
Hydroxychloroquine	82	18.0	18.0
Rifaximin	22	16.5	16.5
Abatacept	129	15.8	15.8
Fentanyl	94	15.8	15.8
Sumatriptan	36	15.0	15.0
Naproxen Sodium	119	14.0	14.0
Azathioprine	73	13.5	13.5
Methotrexate	293	13.5	13.5
Vedolizumab	68	12.8	12.8
Methotrexate Sodium	314	12.7	12.7
Ustekinumab	75	11.9	11.9
Agalsidase Beta	6	10.1	10.1
Romiplostim	7	7.2	7.2
Tofacitinib Citrate	6	7.1	7.1
Golimumab	35	6.4	6.4
Asfotase Alfa	4	6.2	6.2
Guselkumab	10	4.3	4.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.